Clinical Trial

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Study acronym: AMAZE-lung
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
AMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given in a three-weekly regimen. The primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to continued treatment with the third-generation EGFR-TKI lazertinib, in patients with EGFR-mutant advanced NSCLC, who have been previously treated with a third-generation EGFR-TKI in order to provide data on treatment effect and sample size required for a future phase III trial. In addition, the safety of the treatment combination will be evaluated.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2022-10-31; most recent amendment 2026-01-19.
Status change: Recruiting → Active, Not Recruiting 2025-06-30
Status change: Not Yet Recruiting → Recruiting 2023-03-15
Trial Details
NCT Number NCT05601973
Lead Sponsor ETOP IBCSG Partners Foundation
Collaborators: Janssen Pharmaceuticals
Conditions Non Small Cell Lung Cancer
Enrollment 60 participants
Start Date 2023-03-27
Primary Completion 2024-08-24 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-21